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Purpose: To detail the highly variable ocular phenotypes of a French family affected with an autosomal dominantly
inherited vitreoretinopathy and to identify the disease gene.
Methods: Sixteen family members with ten affected individuals underwent detailed ophthalmic evaluation. Genetic
linkage analysis and gene screening were undertaken for genes known to be involved in degenerative and exudative
vitreoretinopathies. Qualitative reverse transcriptase-PCR analysis of the versiscan (VCAN) transcripts was performed
after mutation detection in the VCAN gene.
Results: The first index patient of this French family was referred to us because of a chronic uveitis since infancy; this
uveitis  was  associated  with  exudative  retinal  detachment  in  the  context  of  a  severe  uncharacterized  familial
vitreoretinopathy. Genetic linkage was obtained to the VCAN locus, and we further identified a new pathogenic mutation
at the highly conserved splice acceptor site in intron 7 of the VCAN gene (c.4004–2A>T), which produced aberrantly
spliced VCAN transcripts.
Conclusions:  Extensive  molecular  investigation  allowed  us  to  classify  this  familial  vitreoretinopathy  as  Wagner
syndrome. This study illustrates the need to confirm clinical diagnosis by molecular genetic testing and adds new ocular
phenotypes to the Wagner syndrome, such as vascular and inflammatory features.
Wagner syndrome (OMIM 143200) is a rare dominantly
inherited  vitreoretinopathy  with  complete  penetrance,
characterized by an optically “empty” vitreous with avascular
vitreous strands and veils [1,2]. Typically, the disease begins
in childhood, and patients with Wagner syndrome do not
manifest the orofacial, skeletal and auditory features as those
described  in  Stickler  syndrome  [3].  Other  ocular  clinical
manifestations  are  reported  in  patients  with  Wagner
syndrome,  including  moderate  myopia,  presenile  cataract,
ectopic  fovea,  inverted  papilla,  progressive  chorioretinal
degeneration with atrophy, and retinal detachments. Recently,
the autosomal dominant erosive vitreoretinopathy (OMIM
143200)  has  been  revealed  to  be  allelic  with  Wagner
syndrome [4-7].
The disease gene for Wagner syndrome, recently referred
to as VCAN, codes for a chondroitin sulfate (CS) proteoglycan
termed versican, which belongs to the lectican family of large
aggregating chondrotin sulfate proteoglycans. Structurally,
the core protein of versican is organized as a tridomain with
two globular domains G1 and G3 at the N and C-terminals,
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respectively, and two CS attachment domains CSα and CSβ
in its central area. The N- and C-terminal regions of versican
contain  multiple  motifs  that  can  interact  with  diverse
extracellular matrix and cell-surface structural molecules [8,
9]. Alternative splicing of exons 7 and 8 of the VCAN gene,
coding  for  the  glycoaminoglycan  (GAG)-α  and  GAG-β
domains  respectively,  generates  four  isoforms  of  versican
(V0, V1, V2, and V3) with a different number of chondroitin
sulfate  chains  and  whose  expressions  are  temporally  and
spatially regulated in a specific manner [10-12]. The versican
V0, V1, and V3 isoforms are expressed ubiquitously and
mainly in the later stages of embryonic development [13],
whereas V2 is the predominant versican isoform in the mature
brain  [14].  The  transient  but  elevated  levels  of  versican
expression in various embryonic tissues suggest a central role
of this molecule in tissue morphogenesis, while its decreased
expression after tissue maturation indicates that versican’s
function is implicated in the control of tissue homeostasis
[15,16].
There  is  considerable  evidence  that  differential
expression  of  the  lectican  family  of  chondrotin  sulfate
proteoglycans may be important factors for modulating cell
adhesion as well as axonal growth and guidance during neural
development [17]. In the eye, versican’s expression is found
in the vitreous, the retina, and also in the ciliary body and the
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1669trabecular  meshwork,  but  its  exact  role  in  these  different
ocular  tissues  remains  largely  unknown.  In  the  vitreous,
versican  is  incorporated  into  the  ECM  and  forms  large
aggregates that support vitreous integrity by maintaining the
spatial  organization  of  hyaluronan  and  collagen  fibers.
Versican expression, especially the V0 isoform, which has the
highest  number  of  chondroitin  sulfate  attachment  sites,  is
found in the nerve fiber layer, and the inner plexiform layer
during chicken retinal development, while it is distributed in
the inter-photoreceptor matrix in adult chicken retina [18].
To date, only nine Wagner families have been reported
with the identification of the molecular defect in the VCAN
gene. A total of six different causative mutations, all affecting
either the conserved acceptor splice site of intron 7 or the
donor splice site of intron 8 of the VCAN gene, have been
identified [7,19-22]. It has been demonstrated that these splice
site  mutations  responsible  for  Wagner  syndrome  lead  to
skipping of exon 8, yielding an imbalanced quantitative ratio
of versican transcripts with an increased amount of V2 and
V3 isoforms and haploinsufficiency of V0 and V1 isoforms
[7,19,21]. Therefore, the pathogenic mechanism of Wagner
syndrome is thought to result in a reduction of chondroitin
sulfate side chains, which affect interactions of versican, with
other extracellular components responsible for accelerated
pathologic  liquefaction  of  the  vitreous  gel.  To  better
understand  the  role  of  versican  in  the  physiologic  and
pathological processes in which it is suspected to be involved,
more Wagner families need to be characterized.
We report a four-generation French family presenting a
severe  vitreoretinal  disorder  inherited  as  an  autosomal
dominant trait without evident systemic clinical features. The
first index patient was referred to us because of a chronic
uveitis associated with exudative retinal detachment in the
context of a severe uncharacterized familial vitreoretinopathy.
The clinical diagnosis of the disease presented by this family
was controversial, but genetic linkage was obtained to the
gene for Wagner syndrome. Subsequently, we identified a
novel acceptor splice site mutation in intron 7 of the VCAN
gene (c.4004–2A>T) that produces aberrantly spliced VCAN
transcripts identical to those found in the Japanese Wagner
family with the (c.4004–2A>G) VCAN splice site mutation
[21].  Here,  we  also  detail  unusual  ocular  findings,  which
extend the phenotypic characteristics of Wagner syndrome.
METHODS
Patients: The study followed the tenets of the Declaration of
Helsinki and was approved by the ethics review committee of
the Institutional Review Board of Cochin Hospital (Paris,
France).  Informed  consents  were  obtained  from  all
participating  patients  before  donation  of  blood  samples.
Complete ophthalmologic examinations were performed in
affected and unaffected family members. Kinetic perimetry
was tested with the Goldmann perimeter (Haag-Streit AG,
Bern, Switzerland), and fundus photography was performed
when pupil dilatation was sufficient (Canon fundus camera
with Megaplus model 1.4 digital imaging system, Tokyo,
Japan). Optical coherence tomography imaging was obtained
with the Stratus OCT (Carl Zeiss, San Leandro, CA) and full-
field electroretinography was performed on selected affected
patients with the MonElec2 Monitor Model (Metrovision,
Pérenchies, France). Anterior chamber flare was quantified
with the Kowa FM 500 flare meter (Kowa Company Ltd.,
Tokyo, Japan).
Linkage  analysis:  Genotyping  was  performed  using
fluorescently  tagged  microsatellite  markers,  which  were
previously  reported  or  were  selected  from  the  Marshfield
human genetic linkage map. These markers are closed to the
genes  for  Collagen,  type  II, α-1  ( COL2A1;  D12S1713,
D12S1620),  Frizzled,  Drosophila,  homolog  of,  4  (FZD4;
D11S527, D11S896), low density lipoprotein receptor-related
protein  5  (LRP5;  D11S4076,  D11S4113),  and  versican
(VCAN;  D5S626,  D5S641,  D5S107,  D5S2103).  Linkage
analysis was performed under the assumption of a dominant
model with 100% penetrance and 0.0001 frequency of the
disease allele. Two-point linkage analyses were performed
using the MLINK program from the Linkage package, version
5.1.
Mutation screening: DNAs were extracted from peripheral
blood samples, using the QIAamp DNA mini kit (Qiagen,
Valencia,  CA).  Exons  and  intron–exon  junctions  for  the
FZD4 (two exons, four amplicons), LRPR5 (23 exons, 23
amplicons),  norrin  (NDP;  three  exons,  two  amplicons),
tetraspanin  12  (TSPAN12;  eight  exons,  seven  amplicons)
genes  and  exons  6,  7,  8,  and  9  of  the  VCAN  gene  were
amplified by PCR. PCR primers for VCAN, FZD4, and NDP
exons were developed using the Primer 3 software, and all
these sequences are listed in Table 1, whereas PCR primers
for TSPAN12 and LRP5 exons were designed as described
previously [23,24]. Sequencing reactions were performed in
an  automatic  genetic  analyzer  (ABI  PRISM  3100  genetic
analyzer; Applied Biosystems, Foster City, CA), using the Big
Dye terminator cycle sequencing kit (DNA sequencing kit;
Applied Biosystems).
Qualitative RT–PCR analysis: Total RNA was extracted from
cultured  lymphoblastoid  cells  from  two  affected  family
member’s (V.5 and IV.8) and one control unaffected subject
(V.4),  with  a  commercial  kit  (RNA  Plus;  Q.BIO  gene,
Montreal, Canada). cDNA was synthesized from 1 µg total
RNA  using  random  hexamers  and  M-MLV  reverse
transcriptase (RT, Superscript III; Invitrogen, Carlsbad, CA).
RT–PCR  was  performed  using  different  sets  of  primers
previously designed for specific amplification of each of the
four versican isoforms [21].
RESULTS
Ocular phenotypes: Patient V.5, our index case, was a 29-
year-old  female  patient  who  had  been  referred  to  our
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1670ophthalmologic center for repetitive anterior uveitis with iris–
lens synechiae (Figure 1E). She was moderately myopic and
her intraocular pressure (IOP) was slightly increased with
18 mmHg in her right eye (OD) and 22 mmHg in her left eye
(OS). Laser flare meter measures were four to five times above
normal values: OD 38.5 and OS 50.3 photons/ms. Fine keratic
precipitates were observed in both eyes (OU), and there were
0.5+ cells in the anterior chamber of the right eye and 2+ cells
in the left eye. The patient had a history since the age of 12 of
recurrent alternating attacks of uveitis. These attacks were
successfully treated by topical dexamethasone drops within
7–15 days after the onset of attacks. Additionally, this patient
was followed since early childhood for bilateral vitreoretinal
lesions with peripheral exudative retinal detachments (RDs).
Fluorescein angiography, performed at age 22, did not show
evident interruption of the peripheral retinal vasculature but
revealed  numerous  peripheral  areas  of  exudation,  which
appeared inhomogeneously  hyperfluorescent (Figure 1C,D).
At  that   time,  the   diagnosis  of   her  retinal   disease   was
classified as familial exudative vitreoretinopathy and she had
been  treated  by  bilateral  cryotherapy  at  age  7.  In  our
ophthalmologic center, her fundus examination showed an
optically  empty  vitreous  with  the  presence  of  an  annular
vitreous veil parallel to the ora in both eyes (Figure 1A).
Peripheral exudates associated with areas of pigmentation and
neovascularization  were  predominantly  present  in  the
temporal sector of the retina of both eyes (Figure 1B). Scars
of  cryotherapy  and  laser  were  visible  in  the  inferior  and
superior temporal peripheral retinas. An annular reflex was
seen at the periphery of the macular area, and OCT imaging
showed a densification of the posterior hyaloid, forming a
bridge over the foveal pit (Figure 1F). Goldmann manual
perimetry  showed  normal  peripheral  boundaries  in  the
temporal,  superior,  and  inferior  quadrants,  but  the  nasal
position of the V1e isopter, which was 55° for the right eye,
was  mildly  constricted  to  42°  for  the  left  eye.
Electroretinography  revealed  decreased  scotopic  and
photopic  a  and  b  waves,  with  predominant  left  eye
involvement  (data  not  shown).  An  extensive  workup  to
exclude other causes of uveitis was negative. In particular, the
patient did not carry the HLA B27 allele, her chest CT-scan
and serum angio-convertin enzyme levels were normal, and
numerous serologies for infectious causes of uveitis were
negative.
Patient V.2, a 31-year-old female first cousin of the index
case, had a BCVA of 0.4 in her right pseudophakic eye and
0.25 in her left eye. Because of her family medical history, her
first ophthalmologic examination was performed at the age of
TABLE 1. PRIMER SEQUENCES FOR PCR AMPLIFICATION
Exons Primer name Primer sequence (5′-3′) Product size (bp)
VCAN
6 VCAN_6F tgctcctccaattccttcc 482
  VCAN_6R acatggaatccactccaacg  
7 VCAN_7–1F agcacttaacaaacactgggc 618
  VCAN_7–1R ttccaggatcattcttgcag  
7 VCAN_7–6F caggatttacatcatctttgagtcc 666
  VCAN_7–6R tcttctaatagcagcatttggtatg  
8 VCAN_8–1F gaccagccttgctatcaatttc 605
  VCAN_8–1R ttcctcatggaatgggactg  
8 VCAN_8–11F aatggaagcttctcccacag 600
  VCAN_8–11R acatataaacgttagcaccaagg  
9 VCAN_9F cacgcaaacattagagacgag 243
  VCAN_9R tcgacaacataaattctcccc  
FZD4
1 FZD4_1–2F gtcgccgcatcacactc 516
  FZD4_1–2R ctgtctccttcgggctagg  
2 FZD4_2–1F tggtcaaacttccaagtcattg 615
  FZD4_2–1R gatatcctttcccggcctac  
2 FZD4_2–2F tgaccttcctgatcgattcttc 601
  FZD4_2–2R accccaatcttgaccatcag  
2 FZD4_2–3F ggaactttgttcattgctgc 630
  FZD4_2–3R aactggcttttccattttgg  
NDP
2 NDP_2F ggatcctaggaggtgaagcc 339
  NDP_2R ttctccatcccctgacaaag  
3 NDP_3F caacgagtgtgagggtctttc 397
  NDP_3R ttcttgccagtctttccctg  
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16711 year and showed vitreoretinal exudative lesions; the disease
was  classified  as  familial  exudative  vitreoretinopathy.
Bilateral peripheral cryotherapy was performed at the age of
9 years and was followed by an RD in her left eye, which was
treated by a scleral buckling procedure. An RD of the left eye
was treated by vitrectomy and cryotherapy at the age of 13
years.  Cataract  surgery  by  phacoemulsification  with
placement of a posterior chamber IOL was performed at the
age of 29 years in her right eye. At the time of our examination,
her IOP was 12 mmHg OD and 16 mmHg OS. Laser flare
photometry was minimally increased to 14 photons/ms OD
and  more  significantly  to  39  photons/ms  OS.  Fundus
examination  showed  a  bilateral  nasal  stretching  of  retinal
vessels  with  ectopic  foveae  and  nasal  pigment  clumping
(Figure 2A). The vitreous appeared clear without veils or
strands. OCT imaging showed a similar profile as our index
case, with a densification of the posterior hyaloid forming a
bridge over the foveal pit.
Patient V.6, a 36-year-old female first cousin of the index
case, had a BCVA of 0.6 OD and no light perception in her
left eye. She had a history of RD in her left eye, which was
diagnosed at age 6 and which was unsuccessfully operated on.
Although she had no light perception in that eye, a white
cataract  was  removed  at  the  age  of  33  years  for  esthetic
purposes, without placement of an IOL. Cryotherapy in her
right eye was performed at the age of 8 and 12 years, and this
was later followed by laser photocoagulation of the retinal
periphery.  At  the  time  of  our  examination,  laser  flare
photometry was minimally increased to 12.5 photons/ms OD
and more significantly to 32.3 photons/ms in her left aphakic
eye.  Examination  of  the  fundus  showed  a  clear  vitreous
without strands or veils, and vessels did not appear stretched.
Optic disc pallor was observed in the left eye only. In the right
fundus, retinal atrophy was seen in the peripapillary area and
along the temporal vascular arcades, and this was associated
with  pigment  clumping  (Figure  2B).  In  the  left  eye,  the
chorioretinal  atrophy  was  more  diffuse  and  the  retina
Figure 1. Patient V.5 (the first index case
of  the  family).  A:  Mosaic  multifield
fundus photograph of the patient’s right
eye, showing an avascular vitreous veil,
approximately  2–3  disc  diameters
anterior to the inferior temporal retinal
vein,  with  patches  of  chorioretinal
atrophy,  retinal  pigmentary,  and
exudative lesions. B: Exudative yellow
lesions  with  telangiectatic  Coats-like
neovascularization are seen in the retinal
periphery. C: Fluorescein angiogram of
the right eye of patient V.5 showing the
superior  pole  and  superior  nasal  and
inferior  temporal  periphery.  A  mildly
titled  disc  is  seen.  The  retinal
vasculature  appears  normal  at  the
posterior pole and in the superior nasal
periphery,  and  pigment  clumping  is
present  in  the  inferior  temporal  field.
D: Fluorescein angiogram of the right
eye  of  patient  V.5  showing  pigment
clumping  parallel  to  the  ora  in  the
inferior  nasal  periphery.  Peripheral
vascular leakage is seen as diffuse areas
of  hyperfluorescence.  E:  Slit-lamp
photograph of the left eye of patient V.
5 showing iris–lens synechiae from the
7:00  to  the  10:00  position.  F:  OCT
imaging of the right eye of patient V.5
showing  a  dense  posterior  hyaloid
forming a bridge over the foveal pit.
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1672Figure  2.  Mosaic  multifield  fundus
photographs  of  different  family
members.  A:  Fundus  photograph  of
patient V.2 showing a nasal dragging of
the retinal vessels and fovea with white
perivascular  sheathing.  Clumps  of
pigment are visible in the nasal retina.
No  avascular  vitreous  membrane  was
seen. B: Fundus photograph of the right
eye  of  patient  V.6  showing  a  normal
retinal  vasculature  with  atrophy  and
pigment clumping along and anterior to
the  temporal  arcades.  No  avascular
vitreous  membrane  was  observed.  C:
Fundus photograph of the left eye of
patient  V.6  showing  diffuse
pigmentation  with  chorioretinal
atrophy.
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1673appeared grayish and speckled with pigment clumping, giving
an  aspect  of  pseudo-retinitis  pigmentosa.  OCT  imaging
showed a normal macular profile OD and a thinned atrophic
retina OS.
The medical history and ocular phenotypes of affected
family members of the fourth generation are summarized in
Table 2. At the time of examination in our center, all these
patients were blind and laser flare meter measurements were
found to be increased. All had manifested RDs at an early age,
with  variable  anterior  segment  manifestations,  including
moderate myopia, glaucoma, cataracts, and ectopia lentis.
Linkage  analysis:  As  a  first  step  toward  identifying  the
causative  gene  in  this  four-generation  French  family,  we
performed  linkage  analyses.  Sixteen  family  members,
including  ten  affected  individuals  and  six  unaffected
individuals,  were  genotyped,  and  significant  evidence  of
linkage was shown with markers D5S641 (Z=3.36, ø=0) and
D5S2103 (Z=2.89, ø=0), indicating a critical disease region
for the WGN1 locus on 5q13-q14 (Figure 3A).
DNA sequence analysis: Direct sequencing of the VCAN gene
from the index patient (V.5) DNA sample revealed a novel
heterozygous A>T transversion at the second base of the 3′-
acceptor splice site of intron 7 (c.4004 −2A>T; Figure 3B).
This base pair substitution was present in the ten affected
patients of this family and absent in six unaffected family
members, confirming that it co-segregated with the disease
status. Furthermore, this splice site mutation was not detected
in 100 unrelated French control subjects, supporting that this
sequence  variation  is  pathogenic  and  is  not  a  rare
polymorphism. This mutation occurred in a highly conserved
3′-acceptor splice site of intron 7 and is theoretically expected
to destroy this canonical splice site sequence, causing exon 8
skipping and/or activation of a downstream cryptic acceptor
splice site within exon 8 of the mutant allele. Because of
exudative vascular features in some patients of this family, we
also undertook mutation screening in FZD4, LRP5, NDP, and
TSPAN12  genes,  but  no  pathological  mutations  were
identified.
VCAN transcript analysis: The effects of this novel VCAN
intron  7  splice  site  mutation  were  assessed  by  RT–PCR
analysis from immortalized lymphoblastoid cell total RNAs
generated from two affected individuals (V.5 and IV.8) and
one control subject (V.4). Results of RT–PCR indicated that
the c.4004–2A>T mutation activates a cryptic acceptor splice
site  within  exon  8,  located  39  bp  downstream  from  the
authentic 3′ splice acceptor site. Indeed, electrophoresis in 3%
agarose  Nusieve  gel  of  RT–PCR  products  obtained  with
primer pairs 7F/8R revealed a band of 372 bp and a slightly
shorter fragment of 333 bp in RNA sample from the index
patient, but only one fragment of 372 bp in the control RNA
sample  (Figure  4A).  Direct  sequencing  of  this  shortened
abnormal fragment indicated the loss of the first 39 base pairs
of exon 8 from the mutant allele; this loss was expected to lead
to an in-frame deletion of 13 amino acid residues from the
beginning  of  the  GAG-β  domain  of  the  mature  versican
(Figure  4B).  Additionally,  RT–PCR  analysis  with  primer
pairs 7F/9R revealed a band of 286 bp in the RNA sample
from the index patient, which was not detected in the RNA
control sample, indicating an aberrant expression of a versican
mRNA lacking the entire exon 8 (data not shown).
DISCUSSION
We report the first French family with ocular features of
Wagner  syndrome  segregating  with  a  adenine  to  thymine
transversion at the highly conserved splice acceptor site in
intron 7 of the VCAN gene (c.4004–2A>T). This new single
base pair substitution affects the same nucleotide of the intron
7 splice acceptor site that had been substituted into a guanine
(c.4004–2A>G) in a previously reported Japanese Wagner
family [21]. In the present study, we could confirm that our
new  nucleotide  substitution  produces  aberrantly  spliced
VCAN transcripts identical to those found in the Japanese
Wagner family [21].
This large single kindred demonstrated a range of highly
variable phenotypes, from exudative vascular abnormalities
and diffuse retinal atrophy with pigment clumping to nasally
deviated  retinal  vessels  with  ectopic  foveae,  leading  to
different initial diagnoses of the disease until characterization
of the molecular defect in the VCAN gene was achieved.
Exudative vascular features are unusual phenotypic findings
in  Wagner  syndrome,  and  the  exudative  component  was
significant  enough  that  the  initial  diagnosis  of  autosomal
dominant exudative vitreoretinopathy (FEVR) in our index
case was highly suspected. Indeed, this patient, who was born
at term with normal birthweight and who did not received
oxygen  therapy,  showed  peripheral  retinal  vascular
abnormalities  with  severe  retinal  exudates  leading  to
exudative  retinal  detachment,  telangiectatic
neovascularization,  peripheral  chorioretinal  pigmentation,
straightening of the retinal blood vessels, and situs inversus
similar  to  a  FEVR-like  phenotype.  To  exclude  genetic
heterogeneity in the kindred studied here or a synergistic
effect of an additional mutation in a gene implicated in FEVR,
we performed mutation screening of FZD4, LRP5, NDP, and
TSPAN12  genes,  which  are  known  to  be  responsible  for
FEVR.  We  finally  demonstrated  that  these  heterogeneous
clinical presentations exhibited by this single French kindred
are linked to the same molecular defect in the VCAN gene.
The visual impairment of the disease was highly significant
in our pedigree since, among ten affected family members,
three are totally blind and five other patients have completely
lost vision in one eye. RDs were particularly frequent and
occurred at an early onset in the family studied here, and the
RDs also had a poor surgical prognosis. Therefore, RD in
Wagner syndrome appears to be a more common feature and
one that occurs earlier than previously suggested [22]. Our
first index patient (V.5) had an exudative RD at the age of  30
Molecular Vision 2011; 17:1669-1678 <http://www.molvis.org/molvis/v17/a185> © 2011 Molecular Vision
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1675years,  with  vascular  abnormalities  resembling  Coat’s
telangiectasies in her temporal peripheral retinas. This is the
second  known  case  of  such  vascular  lesions  that  have
previously been described in the original Wagner family [1].
Our index patient also presented with recurrent episodes of
bilateral  anterior  uveitis  with  increased  laser  flare  meter
measurements; all these signs are indicative of a breakdown
of the blood–retinal barrier. Although inflammation is not
typical  of  Wagner  disease,  episodes  of  bilateral  anterior
uveitis  in  two  family  members  affected  with  Wagner
syndrome have been described [20]. Therefore, the family
studied here represents the second case of uveitis associated
with Wagner disease. However, due to the low number of
Wagner families that have been molecularly recognized, it
remains difficult to determine whether uveitis is part of the
disease or rather uveitis occurred coincidentally in the two
Figure  3.  Pedigree  of  the  Wagner
family, linkage and mutation analysis of
the  versican  (VCAN)  gene.  A:  The
pedigree of the family studied consisted
in  ten  affected  and  six  unaffected
participating  individuals,  providing
strong evidence of autosomal dominant
mode  of  inheritance.  Filled  symbols
represent affected individuals, whereas
clear  symbols  refer  to  unaffected
individuals. The arrow indicates the first
proband  examined  in  our
ophthalmologic  center.  Segregation
analysis  of  microsatellite  markers
encompassing  the  WGN1  locus  on
chromosome  5q14.3.  The  disease-
associated  haplotype  is  boxed  and  is
shared between all affected members.
The  genetic  markers  and  the
corresponding allele are listed in map
order.  B:  Partial  sequence
chromatograms  of  intron  7–exon  8
boundary of the VCAN gene from one
affected  individual  (V.5)  and  one
normal control subject (V.4) showing  a
heterozygous  adenine  to  thymine
transversion at the second base of the 3′
acceptor splice site of intron 7 (c.4004–
2A>T).
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1676unrelated  families.  Interestingly,  different  recent  studies
support a role for versican in controlling inflammation and
angiogenesis. Indeed, versican is known to be an abundant
proteoglycan in the blood vessel wall, and it has also been
demonstrated  that  the  C-terminal  G3  domain  of  versican
forms a ternary complex with fibronectin and VEGF, thereby
promoting angiogenesis [15,25,26]. Also of interest, a recent
study has documented that versican can elicit the production
of pro-inflammatory cytokines via its interaction with toll-like
receptor 2 [27]. Moreover, the CS chains attached to the GAG-
α and GAG-β domains of versican are involved in the binding
of a series of cytokines, suggesting that an appropriate balance
of  each  splice  isoform  of  versican  may  be  important  for
regulating inflammatory responses [9].
In  conclusion,  molecular  investigation  of  this  French
family  allowed  us  to  classify  this  severe  uncharacterized
familial vitreoretinopathy as Wagner syndrome. This study
illustrates  the  necessity  to  confirm  clinical  diagnosis  by
molecular genetic testing and adds new ocular phenotypes to
the Wagner syndrome, such as vascular and inflammatory
features. Therefore, phenotype–genotype studies of additional
Wagner  patients  are  necessary  to  establish  whether  such
vascular  and  inflammatory  features  are  consistent
observations in Wagner disease.
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